Literature DB >> 19236563

Phosphodiesterase 10A inhibition modulates the sensitivity of the mesolimbic dopaminergic system to D-amphetamine: involvement of the D1-regulated feedback control of midbrain dopamine neurons.

Florence Sotty1, Liliana P Montezinho, Björn Steiniger-Brach, Jacob Nielsen.   

Abstract

Phosphodiesterase (PDE) 10A is highly expressed in medium spiny neurons of the striatum, at the confluence of the corticostriatal glutamatergic and the midbrain dopaminergic pathways, both believed to be involved in the physiopathology of schizophrenia. There is a growing body of evidence suggesting that targeting PDE10A may be beneficial for the treatment of positive symptoms in schizophrenia. The aim of the present study was to investigate how PDE10A inhibition modulates mesolimbic dopaminergic neurotransmission. We found that the selective PDE10A inhibitor, MP-10, blocked D-amphetamine-induced hyperactivity as well as D-amphetamine-induced dopamine efflux in the nucleus accumbens in a dose-dependent manner. We further investigated the mechanism by which PDE10A inhibition affects dopaminergic neurotransmission. We report that MP-10 potentiated the effect of a high but not a low dose of D-amphetamine on the mean firing rate of dopaminergic neurons recorded from the ventral tegmental area. Similarly, the effect of a high, but not a low dose of D-amphetamine, was completely reversed by the selective D(1) antagonist, SCH23390. These data suggest that the D(1)-regulated feedback control of midbrain dopamine neurons is a critical pathway involved in the modulation of the response of mesolimbic dopamine neurons to D-amphetamine by PDE10A inhibition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19236563     DOI: 10.1111/j.1471-4159.2009.06004.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  17 in total

1.  Effect of PDE10A inhibitors on MK-801-induced immobility in the forced swim test.

Authors:  Barbara Langen; Rita Dost; Ute Egerland; Hans Stange; Norbert Hoefgen
Journal:  Psychopharmacology (Berl)       Date:  2011-11-16       Impact factor: 4.530

2.  Negative modulation of GABAA α5 receptors by RO4938581 attenuates discrete sub-chronic and early postnatal phencyclidine (PCP)-induced cognitive deficits in rats.

Authors:  John P Redrobe; Lisbeth Elster; Kristen Frederiksen; Christoffer Bundgaard; Inge E M de Jong; Garrick P Smith; Anne Techau Bruun; Peter H Larsen; Michael Didriksen
Journal:  Psychopharmacology (Berl)       Date:  2011-11-29       Impact factor: 4.530

Review 3.  Cyclic nucleotide phosphodiesterases: potential therapeutic targets for alcohol use disorder.

Authors:  Rui-Ting Wen; Fang-Fang Zhang; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2018-04-16       Impact factor: 4.530

Review 4.  Phosphodiesterase regulation of alcohol drinking in rodents.

Authors:  Marian L Logrip
Journal:  Alcohol       Date:  2015-05-29       Impact factor: 2.405

5.  In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia.

Authors:  John P Redrobe; Morten Jørgensen; Claus T Christoffersen; Liliana P Montezinho; Jesper F Bastlund; Martin Carnerup; Christoffer Bundgaard; Linda Lerdrup; Niels Plath
Journal:  Psychopharmacology (Berl)       Date:  2014-03-01       Impact factor: 4.530

6.  Phosphodiesterase 10A regulates alcohol and saccharin self-administration in rats.

Authors:  Marian L Logrip; Leandro F Vendruscolo; Joel E Schlosburg; George F Koob; Eric P Zorrilla
Journal:  Neuropsychopharmacology       Date:  2014-01-29       Impact factor: 7.853

7.  Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating.

Authors:  Jodi E Gresack; Patricia A Seymour; Christopher J Schmidt; Victoria B Risbrough
Journal:  Psychopharmacology (Berl)       Date:  2013-12-21       Impact factor: 4.530

8.  Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity.

Authors:  Joshua D Vardigan; Henry S Lange; Spencer J Tye; Steven V Fox; Sean M Smith; Jason M Uslaner
Journal:  Psychopharmacology (Berl)       Date:  2016-04-27       Impact factor: 4.530

9.  Selective inhibition of phosphodiesterase 7 enzymes reduces motivation for nicotine use through modulation of mesolimbic dopaminergic transmission.

Authors:  Roberto Ciccocioppo; Giordano de Guglielmo; Hongwu Li; Miriam Melis; Lucia Caffino; Quienwei Shen; Ana Domi; Fabio Fumagalli; Gregory A Demopulos; George A Gaitanaris
Journal:  J Neurosci       Date:  2021-06-01       Impact factor: 6.167

10.  Selective Effects of PDE10A Inhibitors on Striatopallidal Neurons Require Phosphatase Inhibition by DARPP-32

Authors:  Marina Polito; Elvire Guiot; Giuseppe Gangarossa; Sophie Longueville; Mohamed Doulazmi; Emmanuel Valjent; Denis Hervé; Jean-Antoine Girault; Danièle Paupardin-Tritsch; Liliana R V Castro; Pierre Vincent
Journal:  eNeuro       Date:  2015-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.